Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom (Nasdaq: DXCM) reported preliminary, unaudited Q4 2025 revenue of approximately $1.260 billion, up 13% year-over-year, with U.S. revenue of about $892 million (+11%) and international revenue of about $368 million (+18%). For fiscal 2025, preliminary revenue was approximately $4.662 billion, up 16% year-over-year. The company reiterated 2025 non-GAAP gross profit margin of ~61% and non-GAAP operating margin of 20–21%. For 2026, Dexcom anticipates revenue of $5.16–$5.25 billion (≈11–13% growth) with non-GAAP gross margin of 63–64% and operating margin of 22–23%. Dexcom also noted the initial launch of its G7 15 Day system and continued rollout of Stelo. Audited results and a conference call are scheduled for Feb 12, 2026 at 4:30 p.m. ET.
Dexcom (NASDAQ:DXCM) announced Jake Leach as president and CEO effective Jan. 1, 2026, and outlined 2026 priorities including a reimagined Stelo app with AI-powered personalization and enhanced food logging, expanded integrations, and the pharmacy launch of the Dexcom G7 15 Day continuous glucose monitor, which began shipping to pharmacies in early January 2026. Leach will speak at CES 2026 on Jan. 7 and present at the J.P. Morgan Healthcare Conference on Jan. 12. The release notes prior leadership grew revenue from about $250M to over $4.6B annually under the prior CEO.
Dexcom (NASDAQ:DXCM) launched Dexcom Academy, a personalised learning platform for healthcare professionals to strengthen confidence in continuous glucose monitoring (CGM) and support consistent diabetes care.
The platform is available as a desktop and mobile app in Belgium, Germany, Kingdom of Saudi Arabia, the Netherlands, and Spain, with further EMEA launches planned for 2026. Features include bite-sized modules, certification courses, case-study clinical scenarios, and training on Dexcom G7 and Dexcom ONE+. A 2025 Dexcom survey found 38% of HCPs in surveyed EMEA markets said ongoing education on diabetes technology could help address care challenges.
Dexcom (NASDAQ:DXCM) will launch the Dexcom G7 15 Day continuous glucose monitoring system in the U.S. on Dec. 1, 2025 for people 18 and older, initially through durable medical equipment (DME) providers with full retail availability to follow.
The system offers an industry-leading 15.5 days of sensor wear, an overall MARD of 8.0% for accuracy, Medicare coverage and meets therapeutic CGM category requirements. A study showed 73.9% of sensors lasted the full 15 days while ~26% may not. G7 15 Day connects with select automated insulin delivery systems and adds app features like Apple Watch connectivity, automated activity and medication logging, and a 12-hour replacement grace period.
Dexcom (NASDAQ: DXCM) announced on November 19, 2025 that the FDA cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults 18+ with Type 2 diabetes using glargine U-100 long-acting insulin.
Dexcom Smart Basal uses Dexcom G7 15 Day sensor data plus logged doses to deliver personalized daily dose recommendations and reminders in the G7 15 Day app, and connects with Dexcom Clarity for provider prescribing and configuration. Availability in the US will follow the product launch; international rollout is being explored.
Dexcom (NASDAQ: DXCM) unveiled 16 global diabetes advocates for its World Diabetes Day campaign on November 14, 2025.
The advocates — selected from ~1,000 open-call submissions — span ages 6 to 68, represent Type 1, Type 2 and prediabetes, and come from four continents and five countries. The campaign highlights personal stories and use of Dexcom glucose biosensing technology via editorial portraits and a Los Angeles photoshoot that included visits from Lance Bass and Retta.
More details and individual stories are available at Dexcom.com/WorldDiabetesDay.
Dexcom (NASDAQ: DXCM) announced that as of November 7, 2025 Québec will expand RAMQ coverage to include Dexcom Continuous Glucose Monitoring (CGM) for eligible adults (age 18+) living with type 2 diabetes who are treated with intensive insulin therapy (IIT).
Eligibility requires IIT (at least three injections/day or insulin pump) plus one or more clinical criteria such as unmet HbA1C targets, frequent hypoglycemia, or impaired hypoglycemia awareness. The release highlights Dexcom G7 features including a 30-minute warm-up, predictive Urgent Low Soon alert (3.1 mmol/L within 20 minutes), waterproof rating (submerged up to eight feet for 24 hours), and Apple Watch connectivity.
Dexcom (Nasdaq: DXCM) reported third quarter 2025 results on October 30, 2025 with revenue up 22% YoY to $1.209 billion (20% organic). The company raised full‑year 2025 revenue guidance to $4.630–$4.650 billion (≈15% growth) and updated margin targets: non‑GAAP gross margin ~61%, non‑GAAP operating margin ~20–21%, and adjusted EBITDA margin ~29–30%. GAAP operating income rose to $242.5 million (20.1% of revenue), up 480 bps year‑over‑year. Strategic items included an AI meal‑logging feature, expanded G7 access in Ontario, submission of Dexcom Smart Basal to FDA, and Stelo surpassing $100 million revenue in its first year. Cash, cash equivalents and marketable securities totaled $3.32 billion.
Dexcom (NASDAQ:DXCM) announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.
Dr. Ashley serves as Chair of the Department of Medicine at Stanford, overseeing 15 divisions and over 800 faculty. His work spans precision medicine, data science, AI, and digital health. He has co-founded seven biotechnology companies and co-directs Stanford’s biomedical innovation-translation program, Catalyst.
Dexcom said Dr. Ashley will provide a clinical perspective for strategic guidance on medical technology development and healthcare innovation. Quotes from Eric Topol and President/interim CEO Jake Leach highlight his fit with Dexcom’s growth and focus on advancing metabolic health.
Dexcom (NASDAQ:DXCM) has scheduled its third quarter 2025 earnings release and conference call for October 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time.
Investors can access the conference call via webcast through Dexcom's investor relations website at investors.dexcom.com, or by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114".
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
